Clinical Trial Update: A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease [Phase 2]

View source ↗

Summary

Phase 2A study of ALXN1007 for newly diagnosed acute lower gastrointestinal graft-versus-host disease (GVHD) was terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gigvhd
• Graft-versus-host Disease

Drugs mentioned

• ALXN1007

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Acute Graft-Versus-Host Disease, GIGVHD | Phase 2 | Status: TERMINATED | Results posted: 2017-10-06